Strand Life Sciences has marked an important scientific milestone with the publication of research underpinning CancerSpot™, its multi-cancer early detection test, in the Proceedings of the (US) National Academy of Sciences (PNAS), a top-tier, high-impact scientific journal.
The study conducted over the last 4 years as part of the development and clinical validation for CancerSpot™, involved 43 hospitals across India, and examined the biological factors influencing the detection of cancer-associated signals in the blood.
Cells in the body release short DNA fragments into the blood circulation. A very small fraction of this circulating DNA is contributed by tumor cells, should a tumor be present. CancerSpot™ looks for this DNA to detect cancer presence. Interestingly, in cancer patients, the amount of DNA arising from immune cells also rises substantially, which would be expected to dilute the tumor contribution and thereby hamper cancer detection. This study shows the opposite.
Using blood samples from 1,480 subjects, the study found that even among patients at the same cancer stage, higher levels of circulating DNA were associated with stronger cancer-related signals and greater cancer detection sensitivity. In other words, tumor and immune cell contributions in the circulating DNA appear to rise in synchrony, in cancer patients.
The underlying CancerSpot™ technology
CancerSpot™ combines DNA sequencing with AI to identify methylation patterns, i.e., chemical modifications of DNA, that distinguish cancer cells from normal cells. The study included newly diagnosed patients with any of 14 types of cancer, as well as healthy individuals. On an independent validation cohort, CancerSpot™ demonstrated a very low false positive rate of just 1.4 per cent and detected 72 per cent of patients with cancer. The review of this data by an international panel of experts builds confidence in the rigor and accuracy of the CancerSpot™ methodology, supporting its potential for early detection.
Dr Ramesh Hariharan, CEO, Strand Life Sciences said, “In early cancer detection, clinical utility depends on walking a tightrope: maximizing sensitivity to catch disease early while minimizing false-positives that lead to unnecessary invasive procedures and patient harm. Achieving that balance requires deep scientific insight and rigorous validation. Having our work published in PNAS attests to the rigor of our science and the quality of our clinical evidence, marking a pivotal milestone in our mission to bring reliable, scalable early detection beyond the current standard-of-care, to India.”
Dr Tarang Gianchandani, CEO, Sir H.N. Reliance Foundation Hospital, said “Early detection has the power to transform the future of cancer care. This important research of Strand marks a promising step towards making multicancer detection more accessible and reinforces the immense potential of precision diagnostics. At Sir H. N. Reliance Foundation Hospital, we are committed to bringing together clinical excellence and cutting-edge science to redefine what is possible for our patients. We are proud to partner with Strand and have immense confidence in their ability to translate pioneering research into meaningful clinical breakthroughs. This is a strong testament of the hard work of Indian researchers and scientists and we know that this is just the beginning. Our shared ambition is simple yet profound—to detect cancer earlier, intervene sooner and give more patients the opportunity for better outcomes.”
Dr Sewanti Limaye, Director of Medical & Precision Oncology at Sir H.N. Reliance Foundation Hospital and a co-author of the study said “This research marks an important milestone for India’s contribution to global cancer research in precision-based early cancer detection. By showing that higher circulating cell-free DNA concentrations enrich, rather than dilute, cancer-associated methylation signals, this study challenges a fundamental assumption in liquid biopsy science and opens new possibilities for multicancer early detection. The priority now is to translate this discovery into independently validated screening strategies that improve early diagnosis and patient outcomes.”